Troya, J., Ryan, P., Ribera, E., Podzamczer, D., Hontañón, V., Terrón, J. A., . . . Imaz, A. (2016). Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS One.
استشهاد بنمط شيكاغوTroya, Jesús, et al. "Abacavir/Lamivudine Plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study." PLoS One 2016.
MLA استشهادTroya, Jesús, et al. "Abacavir/Lamivudine Plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study." PLoS One 2016.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.